Alymsys (bevacizumab-maly) vs BAT1706

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Alymsys (bevacizumab-maly)

Marketed by Amneal Pharmaceuticals

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

BAT1706 · Avzivi

Marketed by Bio-Thera Solutions and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03329911 · Phase 3 · completed

This double-blind, randomized Phase 3 trial compared BAT1706, a proposed bevacizumab biosimilar, with EU-sourced Avastin, each with paclitaxel and carboplatin, in 651 patients with advanced non-squamous non-small cell lung cancer. The primary endpoint was overall response rate at week 18, tested for equivalence against pre-specified margins (risk ratio 0.75 to 1.33 or 0.73 to 1.36; risk difference -0.12 to 0.15). Both the risk ratio (1.08, 90% CI 0.94 to 1.24) and the risk difference (0.03, 95% CI -0.04 to 0.11) fell inside the margins, so the equivalence primary was met. Source: the peer-reviewed paper (Cancer Med 2023).

Reported efficacy

Overall Response Rate (Week 18): Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). (met)

Result source: NCT03329911

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlymsys (bevacizumab-maly)BAT1706
PFS, median8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163—Not posted · NCT03329911
OS, median—Not reported—Not posted · NCT03329911
ORR40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163—Not posted · NCT03329911
Duration of response, median—Not reported—Not posted · NCT03329911

PFS, median

Alymsys (bevacizumab-maly)
8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163
BAT1706
—Not posted · NCT03329911

OS, median

Alymsys (bevacizumab-maly)
—Not reported
BAT1706
—Not posted · NCT03329911

ORR

Alymsys (bevacizumab-maly)
40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163
BAT1706
—Not posted · NCT03329911

Duration of response, median

Alymsys (bevacizumab-maly)
—Not reported
BAT1706
—Not posted · NCT03329911
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · BAT1706: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlymsys (bevacizumab-maly)BAT1706
Dropout rate
34.3%a
NCT03296163 · Phase 3
31.7%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—a
NCT03296163 · Phase 3
—
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
18.6%a
NCT03296163 · Phase 3
36.6%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3
musculoskeletal and connective tissue disorders 1.5%
renal and urinary disorders 0.9%
hepatobiliarydisorders 0.3%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alymsys (bevacizumab-maly)

ORR 40.3% (n=315) vs 44.6% (n=312) Avastin @ 18wk
responder rate · % of participants
NCT03296163 · Phase 3
PFS 8.31 vs 8.61 Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3 · converted to months from 36 weeks as posted
Overall Survival NA vs NA Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3

BAT1706

ORR 44.6% (n=325) vs 47.9% (n=326) EU Avastin® @ 18wk
event count · % of participants
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to % from 145 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · BAT1706's landscape